Fig. 3From: Relevant mediators involved in and therapies targeting the inflammatory response induced by activation of the NLRP3 inflammasome in ischemic strokePossible drug actions targeting the different mechanisms of NLRP3 inflammasome activation. EPA: eicosapentaenoic acid; MNS: 3,4-methylenedioxy-beta-nitrostyrene; ω-3FAs: omega-3 fatty acids; ARC: arctigenin; SINO: sinomenine; Nrf2: nuclear factor erythrocyte 2–related factor 2; BHB: β-hydroxybutyrate; NM: nafamostat mesilate; IFN-β: interferon-β; UMB: umbelliferone; Eze: ezetimibe; IVIG: intravenous immunoglobulin; GDL: ginkgo diterpene lactones; DAMP: damage-associated molecular pattern; GPR40/GPR20: G protein–coupled receptor (GPCR) 40/20; ASIC: acid-sensing ion channel; CasR/GPR6CA: Ca2+-sensing receptor/GPCR family C group 6 member A; NCX: Na+/Ca2+ exchanger; IL-18R: interleukin-18 receptor; IL-1R: interleukin-1 receptor; TLR4: Toll-like receptor 4; NF-κB: nuclear factor kappa B; MAPK: mitogen-activated protein kinase; PIP2: phosphatidylinositol-4,5-diphosphate; PLC: phospholipase C; DAG: diacylglycerol; InsP3: inositol triphosphate 3; ROS: reactive oxygen species; ASC: apoptosis-associated speck-like protein with a CARD; PKR: protein kinase R; TXNIP: thioredoxin-interacting protein; Bcl-2: B-cell lymphoma 2; Casp 1: caspase-1; GSDMD: gasdermin DBack to article page